Bristol-Myers Squibb Company (BMY) — Stock Price, Chart & Analysis
Bristol-Myers Squibb Company (BMY) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $132.20B and a trailing P/E ratio of 14.13. Over the past 52 weeks, BMY has traded between $42.52 and $68.10. Bristol-Myers Squibb Company pays a dividend yielding 3.9%. View the live BMY chart, technical opinion, analyst ratings, fundamentals and latest news below.
Bristol-Myers Squibb Company (BMY) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $132.20B |
| P/E ratio (TTM) | 14.13 |
| EPS (TTM) | $4.58 |
| Dividend yield | 3.9% |
| 52-week high | $68.10 |
| 52-week low | $42.52 |
| Beta | 0.23 |
| Avg. volume | 12.38M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about Bristol-Myers Squibb Company (BMY)
How much does one share of Bristol-Myers Squibb Company cost?
As of the latest update, one share of Bristol-Myers Squibb Company (BMY) trades at $100 (+0.00% today).
What is Bristol-Myers Squibb Company's market cap?
Bristol-Myers Squibb Company has a market capitalization of approximately $132.20B.
What is Bristol-Myers Squibb Company's P/E ratio?
Bristol-Myers Squibb Company has a trailing price-to-earnings (P/E) ratio of 14.13.
What is Bristol-Myers Squibb Company's earnings per share (EPS)?
Bristol-Myers Squibb Company's trailing twelve-month EPS is $4.58.
Does Bristol-Myers Squibb Company pay a dividend?
Yes — Bristol-Myers Squibb Company pays a dividend with a yield of 3.9% ($2.52 per share annually).
What is Bristol-Myers Squibb Company's 52-week trading range?
Over the past year, BMY has traded between $42.52 and $68.10.
What is the analyst price target for Bristol-Myers Squibb Company?
The mean analyst price target for Bristol-Myers Squibb Company is $66.21. This is informational only and not investment advice.
Latest Bristol-Myers Squibb Company (BMY) news
- Xenon Pharmaceuticals Q2 Earnings Call HighlightsNews · Aug 7, 2026
- Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.News · Aug 7, 2026
- CYTK Q2 Earnings Top Estimates, Myqorzo Uptake StrongNews · Aug 7, 2026
- PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in FocusNews · Aug 7, 2026
- These New Drugs Could Fuel Fresh Highs for Biotech and Pharma StocksNews · Aug 7, 2026
- AstraZeneca (LSE:AZN) Merger Talk Fades, Is The Stock Undervalued?News · Aug 7, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live BMY dashboard…